https://mb.cision.com/Public/18595/3664497/8a15d6f32cb1113b_800x800ar.png
** Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phas=
e 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthriti=
s and Ankylosing Spondylitis
------------------------------------------------------------
=C2=B7 New late-breaking 52-week data from Phase 3 bimekizumab investigatio=
nal studies in psoriatic arthritis and across the spectrum of axial spondyl=
oarthritis, including non-radiographic axial spondyloarthritis and ankylosi=
ng spondylitis, presented at ACR Convergence 2022
=C2=B7 In BE OPTIMAL, clinical joint and skin clearance responses in psoria=
tic arthritis were sustained to week 52 with bimekizumab treatment=C2=A0
=C2=B7 In BE MOBILE 1 and BE MOBILE 2, treatment with bimekizumab resulted =
in sustained clinical responses to week 52, including suppression of inflam=
mation and improvements in function and quality of life across the full spe=
ctrum of axial spondyloarthritis=C2=A0
=C2=B7 The adverse event profile of bimekizumab to week 52 in psoriatic art=
hritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis=
is consistent with previous observations with no new safety signals
Brussels (Belgium), 10th November 2022 =E2=80=93 07:00 (CET) =C2=A0=E2=80=
=93 UCB, a global biopharmaceutical company, today announced the first pres=
entation of long-term, 52-week data from three Phase 3 studies evaluating t=
he efficacy and safety of bimekizumab in adults with active psoriatic arthr=
itis (PsA) who were biologic-na=C3=AFve (BE OPTIMAL), in adults with active=
non-radiographic axial spondyloarthritis (nr-axSpA; BE MOBILE 1), and in a=
dults with active ankylosing spondylitis, also known as radiographic axSpA =
(AS; BE MOBILE 2).^1,2 These late-breaking data are being presented at ACR =
Convergence 2022 in Philadelphia, November 10=E2=80=9314, 2022.^1,2 The saf=
ety and efficacy of bimekizumab in PsA, nr-axSpA and AS have not been estab=
lished, and it is not approved for use in PsA, nr-axSpA or AS by any regula=
tory authority worldwide.
Data from BE OPTIMAL showed that clinical joint and skin clearance response=
s in patients with active psoriatic arthritis were sustained to week 52 wit=
h bimekizumab treatment.^1 In addition, data from BE MOBILE 1 and BE MOBILE=
2, showed that across the full spectrum of axSpA, encompassing nr-axSpA an=
d AS, treatment with bimekizumab resulted in sustained improvement in the s=
igns and symptoms of disease, including suppression of inflammation and imp=
rovements in physical function and quality of life, to week 52.^2 These out=
comes were consistent across both TNF-inhibitor (TNFi) na=C3=AFve and TNFi-=
inadequate responder populations.^2 In all three studies, the adverse event=
profile of bimekizumab was consistent with data seen in previous studies w=
ith no new observed signals.^1,2=C2=A0
=E2=80=9CThe 52-week data shared today demonstrate the high thresholds of d=
isease control that were achieved by the majority of patients across these =
three studies. The results build on the previously announced 24-week data a=
nd show that bimekizumab sustained a clinically meaningful impact for patie=
nts through one year,=E2=80=9D said Emmanuel Caeymaex, Executive Vice Presi=
dent, Immunology Solutions and Head of U.S., UCB.
BE OPTIMAL (PsA): Phase 3 Study Results (52 weeks)^1=C2=A0
In BE OPTIMAL, patients were randomized (3:2:1) to bimekizumab (160 mg ever=
y four weeks [Q4W]; N=3D431), placebo (N=3D281) or the active reference arm=
(adalimumab 40 mg every two weeks [Q2W]; N=3D140). Patients initially rand=
omized to placebo were switched to bimekizumab at week 16. A total of 89.3 =
percent of randomized patients completed week 52. Key 52-week results from =
the BE OPTIMAL study are presented below and build upon previously announce=
d 16- and 24-week results (https://www.ucb.com/stories-media/Press-Releases=
/article/UCB-Announces-First-Detailed-Data-from-Two-Phase-3-Bimekizumab-Stu=
dies-in-Psoriatic-Arthritis-to-be-Presented-at-EULAR-2022) .
=C2=B7 ACR50: At week 52, 54.5 percent of patients continuously treated wit=
h bimekizumab, 53.0 percent of patients who switched from placebo to bimeki=
zumab at week 16, and 50.0 percent of patients in the reference arm (adalim=
umab) achieved ACR50.=C2=A0
=C2=B7 Complete Skin Clearance (PASI 100): At week 52, in patients with bas=
eline psoriasis =E2=89=A53 percent body surface area^=C2=A5, 60.8 percent o=
f patients continuously treated with bimekizumab, 65.0 percent of patients =
who switched from placebo to bimekizumab at week 16, and 48.5 percent of pa=
tients in the reference arm (adalimumab) achieved PASI 100.=C2=A0
=C2=B7 Minimal Disease Activity (MDA): At week 52, 55.0 percent of patients=
continuously treated with bimekizumab, 53.7 percent of patients who switch=
ed from placebo to bimekizumab at week 16, and 52.9 percent of patients in =
the reference arm (adalimumab) achieved MDA.
=E2=80=9CThe long-term bimekizumab data presented at ACR Convergence 2022 i=
n patients with psoriatic arthritis show clinically meaningful improvements=
in joint and skin outcomes through to one year. In BE OPTIMAL, at week 52,=
over six out of 10 patients treated with bimekizumab achieved complete ski=
n clearance and one in two patients achieved minimal disease activity. Long=
-term data such as these are important since they may help to inform clinic=
al decision making of the future,=E2=80=9D said Christopher Ritchlin MD, MP=
H, Professor of Medicine and faculty member in the Allergy, Immunology & Rh=
eumatology Division, University of Rochester Medical School, Rochester, New=
York, U.S.
Over 52 weeks, 79.1 percent of patients treated with bimekizumab had =E2=89=
=A5 one treatment emergent adverse event (TEAE) and 80.7 percent on adalimu=
mab.^1 The three most frequent TEAEs with bimekizumab treatment were nasoph=
aryngitis (12.0 percent), upper respiratory tract infection (7.1 percent) a=
nd urinary tract infection (6.1 percent).^1 =C2=A0
BE MOBILE 1 and BE MOBILE 2 (axSpA): Phase 3 Study Results (52 weeks)^2
In BE MOBILE 1 and BE MOBILE 2, patients were randomized to bimekizumab (16=
0 mg Q4W; N=3D128 for BE MOBILE 1 and N=3D221 for BE MOBILE 2) or to placeb=
o (N=3D126 for BE MOBILE 1 and N=3D111 for BE MOBILE 2). Patients initially=
randomized to placebo were switched to bimekizumab at week 16. A total of =
86.6 percent randomized patients with nr-axSpA and 89.8 percent with AS com=
pleted week 52. Key 52-week results from the BE MOBILE 1 and BE MOBILE 2 st=
udies are presented below and build upon previously announced 16- and 24-we=
ek results (https://www.ucb.com/stories-media/Press-Releases/article/First-=
Presentations-of-Phase-3-Data-for-Bimekizumab-Across-the-Full-Spectrum-of-A=
xial-Spondyloarthritis-to-be-Shared-at-EULAR-2022) :
=C2=B7 ASAS40: At week 52, 60.9 percent of nr-axSpA patients and 58.4 perce=
nt of AS patients continuously treated with bimekizumab achieved ASAS40, wi=
th consistent outcomes across both TNFi-na=C3=AFve and TNFi-inadequate resp=
onder populations.=C2=A0
=C2=B7 Low Disease Activity and Remission: At week 52, 61.6 percent of nr-a=
xSpA patients and 57.1 percent of AS patients continuously treated with bim=
ekizumab achieved low disease activity (ASDAS<2.1); at week 52, inactive di=
sease or clinical remission (ASDAS<1.3) was achieved by 25.2 percent of nr-=
axSpA patients and 23.4 percent of AS patients continuously treated with bi=
mekizumab.
=C2=B7 Objective Inflammation: The reductions from baseline in objective si=
gns of inflammation (Magnetic Resonance Imaging [MRI], hs-C-Reactive Protei=
n [hs-CRP]) for patients with nr-axSpA and AS were sustained through week 5=
2.
In addition, improvements in function as measured by the Bath Ankylosing Sp=
ondylitis Functional Index (BASFI) and quality of life, as measured by Anky=
losing Spondylitis Quality of Life (ASQoL), were sustained through week 52.
=E2=80=9CResults presented today from BE MOBILE 1 and BE MOBILE 2 demonstra=
te that treatment with bimekizumab provided consistent and sustained improv=
ements to one year in key signs and symptoms across the full spectrum of ax=
ial spondyloarthritis, with similar outcomes regardless of previous treatme=
nt with TNF inhibitors. These positive results are the first Phase 3 data e=
valuating a dual IL-17A and IL-17F inhibitor, bimekizumab, in the long-term=
treatment of patients living with non-radiographic axial spondyloarthritis=
and ankylosing spondylitis,=E2=80=9D said Professor Xenofon Baraliakos, Rh=
eumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany.
Over 52 weeks, 75.0 percent of nr-axSpA patients treated with bimekizumab a=
nd 75.5 percent of AS patients had =E2=89=A51 TEAE.^2 The most frequent TEA=
Es were nasopharyngitis (nr-axSpA 12.3 percent; AS 9.1 percent), upper resp=
iratory tract infection (nr-axSpA 9.4 percent; AS 6.4 percent) and oral can=
didiasis (nr-axSpA 7.4 percent; AS 6.1 percent); few COVID-19 infections we=
re reported (nr-axSpA: 7.0 percent; AS; 2.1 percent).^2 The incidence of se=
rious TEAEs was low (nr-axSpA 4.4 percent; AS 7.1 percent).^2 =C2=A0
Notes to editors:
The primary endpoint in the BE OPTIMAL study was ACR50 at week 16 with rank=
ed secondary endpoints including PASI90 and MDA at week 16; the primary end=
point in the BE MOBILE 1 and BE MOBILE 2 studies was ASAS40 at week 16.
^=C2=A5In patients with psoriasis affecting =E2=89=A53% body surface area a=
t baseline; n=3D217 for patients continuing treatment with bimekizumab; n=
=3D140 for patients switching from placebo to bimekizumab at week 16 and n=
=3D68 for patients continuing treatment with adalimumab=C2=A0
About Psoriatic Arthritis
Psoriatic arthritis (PsA) is a serious, highly heterogeneous, chronic syste=
mic inflammatory condition affecting both the joints and skin, with a preva=
lence of 0.02 percent to 0.25 percent of the population, and 6 percent to 4=
1 percent of patients with psoriasis.^3 Symptoms include joint pain and sti=
ffness, skin plaques, swollen toes and fingers (dactylitis), and inflammati=
on of the sites where tendons or ligaments insert into the bone (enthesitis=
).^4
About Axial Spondyloarthritis
Axial Spondyloarthritis (axSpA), which includes both non-radiographic axSpA=
and ankylosing spondylitis (AS), also known as radiographic axSpA (r-axSpA=
), is a chronic, immune-mediated, inflammatory disease.^5 nr-axSpA is defin=
ed clinically by the absence of definitive x-ray evidence of structural dam=
age to the sacroiliac joints.^5 AxSpA is a painful condition that primarily=
affects the spine and the joints linking the pelvis and lower spine (sacro=
iliac joints).^5 The leading symptom of axSpA in a majority of patients is =
inflammatory back pain that improves with exercise, but not with rest.^5 Ot=
her common clinical features frequently include anterior uveitis, enthesiti=
s, peripheral arthritis, psoriasis, inflammatory bowel disease and dactylit=
is.^5 The overall prevalence of axSpA is 0.3 percent to 1.2 percent of adul=
ts.^6,7 Approximately half of all patients with axSpA are patients with nr-=
axSpA.^5 AxSpA onset usually occurs before the age of 45.^5 Approximately 1=
0 to 40 percent of patients with nr-axSpA progress to ankylosing spondyliti=
s over 2 to 10 years.^5
About bimekizumab
Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to sel=
ectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F)=
, two key cytokines driving inflammatory processes.^8,9 In August 2021, bim=
ekizumab was approved in the European Union (EU)/European Economic Area (EE=
A) and in Great Britain, for the treatment of moderate to severe plaque pso=
riasis in adults who are candidates for systemic therapy.^9,10 The label in=
formation may differ in other countries. Please check local prescribing inf=
ormation. In the U.S., the efficacy and safety of bimekizumab have not been=
established for any indication and it is not approved by the U.S. Food and=
Drug Administration (FDA).
BIMZELX^=C2=AE =E2=96=BC(bimekizumab) EU/EEA Important Safety Information i=
n Psoriasis^9
The most frequently reported adverse reactions with bimekizumab were upper =
respiratory tract infections (14.5%) (most frequently nasopharyngitis) and =
oral candidiasis (7.3%). Common adverse reactions (=E2=89=A51/100 to <1/10)=
were oral candidiasis, tinea infections, ear infections, herpes simplex in=
fections, oropharyngeal candidiasis, gastroenteritis, folliculitis, headach=
e, dermatitis and eczema, acne, injection site reactions and fatigue. Elder=
ly may be more likely to experience certain adverse reactions such as oral =
candidiasis, dermatitis and eczema when using bimekizumab.
Bimekizumab is contraindicated in patients with hypersensitivity to the act=
ive substance or any of the excipients and in patients with clinically impo=
rtant active infections (e.g. active tuberculosis).=C2=A0
Bimekizumab may increase the risk of infections. Treatment with bimekizumab=
must not be administered in patients with any clinically important active =
infection. Patients treated with bimekizumab should be instructed to seek m=
edical advice if signs or symptoms suggestive of an infection occur. Prior =
to initiating treatment with bimekizumab, patients should be evaluated for =
tuberculosis (TB) infection. Bimekizumab should not be given in patients wi=
th active TB and patients receiving bimekizumab should be monitored for sig=
ns and symptoms of active TB.=C2=A0
Cases of new or exacerbations of inflammatory bowel disease have been repor=
ted with bimekizumab. Bimekizumab is not recommended in patients with infla=
mmatory bowel disease. If a patient develops signs and symptoms of inflamma=
tory bowel disease or experiences an exacerbation of pre-existing inflammat=
ory bowel disease, bimekizumab should be discontinued and appropriate medic=
al management should be initiated. Serious hypersensitivity reactions inclu=
ding anaphylactic reactions have been observed with IL-17 inhibitors. If a =
serious hypersensitivity reaction occurs, administration of bimekizumab sho=
uld be discontinued immediately and appropriate therapy initiated.=C2=A0
Live vaccines should not be given in patients treated with bimekizumab.
Please consult the summary of product characteristics in relation to other =
side effects, full safety and prescribing information. https://www.ema.euro=
pa.eu/en/documents/product-information/bimzelx-epar-product-information_en.=
pdf
EU summary of product characteristics date of revision: May 2022.
Last accessed: November 2022.=C2=A0=C2=A0 =C2=A0
=E2=96=BC=C2=A0This medicinal product is subject to additional monitoring. =
This will allow quick identification of new safety information. Healthcare =
professionals are asked to report any suspected adverse reactions=C2=A0
For further information, contact UCB:=C2=A0
Investor Relations
Antje Witte
T +32.2.559.94.14=C2=A0
email antje.witte@ucb.com=C2=A0
Corporate Communications
Laurent Schots=C2=A0
T +32.2.559.92.64=C2=A0
email laurent.schots@ucb.com
Brand Communications
Eimear O=E2=80=99Brien
T +32.2.559.92.71
email eimear.obrien@ucb.com=C2=A0
About UCB=C2=A0
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With approximately 8,600 peopl=
e in approximately 40 countries, the company generated revenue of =E2=82=AC=
5.8 billion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Foll=
ow us on Twitter: @UCB_news.
Forward looking statements=C2=A0
This press release may contain forward-looking statements including, withou=
t limitation, statements containing the words =E2=80=9Cbelieves=E2=80=9D, =
=E2=80=9Canticipates=E2=80=9D, =E2=80=9Cexpects=E2=80=9D, =E2=80=9Cintends=
=E2=80=9D, =E2=80=9Cplans=E2=80=9D, =E2=80=9Cseeks=E2=80=9D, =E2=80=9Cestim=
ates=E2=80=9D, =E2=80=9Cmay=E2=80=9D, =E2=80=9Cwill=E2=80=9D, =E2=80=9Ccont=
inue=E2=80=9D and similar expressions. These forward-looking statements are=
based on current plans, estimates and beliefs of management. All statement=
s, other than statements of historical facts, are statements that could be =
deemed forward-looking statements, including estimates of revenues, operati=
ng margins, capital expenditures, cash, other financial information, expect=
ed legal, arbitration, political, regulatory or clinical results or practic=
es and other such estimates and results. By their nature, such forward-look=
ing statements are not guarantees of future performance and are subject to =
known and unknown risks, uncertainties and assumptions which might cause th=
e actual results, financial condition, performance or achievements of UCB, =
or industry results, to differ materially from those that may be expressed =
or implied by such forward-looking statements contained in this press relea=
se. Important factors that could result in such differences include: the gl=
obal spread and impact of COVID-19, changes in general economic, business a=
nd competitive conditions, the inability to obtain necessary regulatory app=
rovals or to obtain them on acceptable terms or within expected timing, cos=
ts associated with research and development, changes in the prospects for p=
roducts in the pipeline or under development by UCB, effects of future judi=
cial decisions or governmental investigations, safety, quality, data integr=
ity or manufacturing issues; potential or actual data security and data pri=
vacy breaches, or disruptions of our information technology systems, produc=
t liability claims, challenges to patent protection for products or product=
candidates, competition from other products including biosimilars, changes=
in laws or regulations, exchange rate fluctuations, changes or uncertainti=
es in tax laws or the administration of such laws, and hiring and retention=
of its employees. There is no guarantee that new product candidates will b=
e discovered or identified in the pipeline, will progress to product approv=
al or that new indications for existing products will be developed and appr=
oved. Movement from concept to commercial product is uncertain; preclinical=
results do not guarantee safety and efficacy of product candidates in huma=
ns. So far, the complexity of the human body cannot be reproduced in comput=
er models, cell culture systems or animal models. The length of the timing =
to complete clinical trials and to get regulatory approval for product mark=
eting has varied in the past and UCB expects similar unpredictability going=
forward. Products or potential products, which are the subject of partners=
hips, joint ventures or licensing collaborations may be subject to differen=
ces disputes between the partners or may prove to be not as safe, effective=
or commercially successful as UCB may have believed at the start of such p=
artnership. UCB=E2=80=99s efforts to acquire other products or companies an=
d to integrate the operations of such acquired companies may not be as succ=
essful as UCB may have believed at the moment of acquisition. Also, UCB or =
others could discover safety, side effects or manufacturing problems with i=
ts products and/or devices after they are marketed. The discovery of signif=
icant problems with a product similar to one of UCB=E2=80=99s products that=
implicate an entire class of products may have a material adverse effect o=
n sales of the entire class of affected products. Moreover, sales may be im=
pacted by international and domestic trends toward managed care and health =
care cost containment, including pricing pressure, political and public scr=
utiny, customer and prescriber patterns or practices, and the reimbursement=
policies imposed by third-party payers as well as legislation affecting bi=
opharmaceutical pricing and reimbursement activities and outcomes. Finally,=
a breakdown, cyberattack or information security breach could compromise t=
he confidentiality, integrity and availability of UCB=E2=80=99s data and sy=
stems.=C2=A0
Given these uncertainties, you should not place undue reliance on any of su=
ch forward-looking statements. There can be no guarantee that the investiga=
tional or approved products described in this press release will be submitt=
ed or approved for sale or for any additional indications or labelling in a=
ny market, or at any particular time, nor can there be any guarantee that s=
uch products will be or will continue to be commercially successful in the =
future.
UCB is providing this information, including forward-looking statements, on=
ly as of the date of this press release and it does not reflect any potenti=
al impact from the evolving COVID-19 pandemic, unless indicated otherwise. =
UCB is following the worldwide developments diligently to assess the financ=
ial significance of this pandemic to UCB. UCB expressly disclaims any duty =
to update any information contained in this press release, either to confir=
m the actual results or to report or reflect any change in its forward-look=
ing statements with regard thereto or any change in events, conditions or c=
ircumstances on which any such statement is based, unless such statement is=
required pursuant to applicable laws and regulations.=C2=A0
Additionally, information contained in this document shall not constitute a=
n offer to sell or the solicitation of an offer to buy any securities, nor =
shall there be any offer, solicitation or sale of securities in any jurisdi=
ction in which such offer, solicitation or sale would be unlawful prior to =
the registration or qualification under the securities laws of such jurisdi=
ction.=C2=A0
References=C2=A0
1. Ritchlin C, Coates L, McInnes I, et al. Bimekizumab treatment in biologi=
c DMARD-na=C3=AFve patients with active psoriatic arthritis: 52-week effica=
cy and safety results from a Phase 3, randomized, placebo-controlled, activ=
e reference study. #L02 Presented at ACR Convergence 2022. https://acrabstr=
acts.org/abstract/bimekizumab-treatment-in-biologic-dmard-naive-patients-wi=
th-active-psoriatic-arthritis-52-week-efficacy-and-safety-results-from-a-ph=
ase-3-randomized-placebo-controlled-active-reference-study/=C2=A0
=C2=A0
2. Baraliakos X, Deodhar A, van der Heijde D, et al. Bimekizumab maintains =
improvements in efficacy endpoints and has a consistent safety profile thro=
ugh 52 weeks in patients with non-radiographic axial spondyloarthritis and =
ankylosing spondylitis: results from two parallel Phase 3 studies. #L14 Pre=
sented at ACR Convergence 2022. https://acrabstracts.org/abstract/bimekizum=
ab-maintains-improvements-in-efficacy-endpoints-and-has-a-consistent-safety=
-profile-through-52-weeks-in-patients-with-non-radiographic-axial-spondyloa=
rthritis-and-ankylosing-spondylitis-resu/=C2=A0
3. Ogdie A, Weiss P. The Epidemiology of Psoriatic Arthritis. Rheum Dis Cli=
n North Am. 2015; 41(4): 545=E2=80=93568.
4. Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the di=
agnosis and pharmacologic treatment of psoriatic arthritis in patients with=
psoriasis. Drugs. 2014; 74:423-441.
5. Deodhar A. Understanding Axial Spondyloarthritis: A Primer for Managed C=
are. Am J Manag Care. 2019;25:S319-S330.
6. Reveille J, Witter J, Weisman M. Prevalence of axial spondylarthritis in=
the United States: estimates from a cross-sectional survey. Arthritis Care=
Res. 2012;64(6):905-910.
7. Hamilton L, Macgregor A, Toms A, et al. The prevalence of axial spondylo=
arthritis in the UK: a cross-sectional cohort study. BMC Musculoskelet Diso=
rd. 2015;21;16:392.
8. Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of bi=
mekizumab, a humanized monoclonal =C2=A0 =C2=A0antibody and selective dual =
inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 201=
7;83(5):991-1001.
9. BIMZELX^=C2=AE (bimekizumab) EU Summary of Product Characteristics.=C2=
=A0https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-=
product-information_en.pdf. Last accessed: November 2022.
10. BIMZELX^=C2=AE (bimekizumab) GB Summary of Product Characteristics. htt=
ps://www.medicines.org.uk/emc/product/12834; https://www.medicines.org.uk/e=
mc/product/12833. Last accessed: November 2022.
GenericFile
UCB PR ACR 2022 ENG (https://mb.cision.com/Public/18595/3664497/b625afe91f4=
02dbd.pdf)
______________________
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x121320x1x6868579x2400=
0x6&Email=3Dregnews%40symexglobal.com.
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium